http://www.fda.gov/cder/orange/appendix_a.txt IRRIGANT, NEOMYCIN SULFATE NEOSPORIN, BACITRACIN ZINC NEOSPORIN, GRAMICIDIN NEOSPORIN, NEOMYCIN SULFATE (OTC) NEOTHYLLINE, DYPHYLLINE NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE) NEPHRAMINE 5.4%, AMINO ACIDS NEPHROFLOW, IODOHIPPURATE SODIUM, I-123 NEPTAZANE, METHAZOLAMIDE NESACAINE, CHLOROPROCAINE HYDROCHLORIDE NESACAINE-MPF, CHLOROPROCAINE...
Product Description OTC CATALOGUE SEARCH PRODUCT PRODUCTS FAQ (CONSUMERS) NEW PRODUCTS FAMILY HEALTH CORNER WOMEN'S HEALTH ALLERGIES COUGH, COLD CROMOLYN ANTI-ALLERGIC Part Code : 5760692770 Therapeutic Class : Cough - Cold / Allergies Product Class : Consumer Compares to : Opticrom Form : Drops Strength : 2% w/v Format : 5mL UPC : 057606927705 DIN : 02009277 Click here to print - -©...
Product Description OTC CATALOGUE SEARCH PRODUCT PRODUCTS FAQ (CONSUMERS) NEW PRODUCTS FAMILY HEALTH CORNER WOMEN'S HEALTH ALLERGIES COUGH, COLD CROMOLYN ANTI-ALLERGIC Part Code : 5760636074 Therapeutic Class : Cough - Cold / Allergies Product Class : Consumer Compares to : Opticrom Form : Drops Strength : 2% w/v Format : 10mL UPC : 057606360748 DIN : 02009277 Click here to print - -©...
Reference Listed Drug Labeling Approved in February 2001 letter label meropenem for injection 50-706 S-007 SUPRAX letter label cefixime oral suspension 50-622 S-014 VANCOCIN HCL letter label vancomycin hydrochloride capsules 50-606 S-014 ZYVOX letter label linezolid tablets linezolid injection linezolid for oral suspension 21-130 21-131 21-132 S-001 S-001 S-001 Feb 8 AVANDIA letter label rosiglitazone maleate tablets 21-071 S-006...
author: USERNAME
FDA Drug Approvals List February 2001 Approvable Original New Drug Applications - Original Abbreviated New Drug Applications Original Abbreviated Application # 075402 Approval Date: 28-FEB-01 Trade Name: METAPROTERENOL SULFATE Dosage Form: SOLUTION Applicant: NOVEX PHARMA Active Ingredient(s): METAPROTERENOL SULFATE OTC/RX Status: RX Original Abbreviated Application # 075403 Approval Date: 28-FEB-01 Trade Name:...
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf OPTlCROM (cromol n sodium ophthalmic solution, USP) 4% Sterile D SCRIPTION OPTICROM ( cro olyn sodiu ic solution, USP) 4% is a clear, colorless, sterile solution intended or topical ophthal ic useOPTICROM is indicated in the treat ent o keratoconjunctivitis, vernal conjunctivitis, and vernal keratitisOPTICROM is...
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 5
http://www.fda.gov/cder/foi/appletter/2001/18155s22ltr.pdf page 1
Prescription and OTC Drug Product List 1/1998 Prescription and Over-the-Counter Drug Product List - 18th Edition Cumulative Supplement Number 1: Jan 1998 [ Prescription - OTC ] ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACARBOSE ALPROSTADIL TABLET; ORAL INJECTABLE; INJECTION PRECOSE PROSTIN VR PEDIATRIC - DLT - @ BAYER 25MG N20482 004 - DLT - + PHARMACIA AND UPJOHN 0.5MG/ML N18484 001 - DLT - MAY 29, 1997 - ADD -...
http://www.fda.gov/cder/foi/appletter/2000/75615ltr.pdf ANDA 75- 615 January 26, 2001 Apotex CorpCromolyn Sodium Ophthalmic Solution USP, 4%
http://www.fda.gov/cder/foi/appletter/2000/75615ltr.pdf page 1
75282.AP.DOC ANDA 75- 282 June 16, 1999 Alcon Laboratories, IncCromolyn Sodium Ophthalmic Solution USP, 4%
author: Unknown
75282.AP.DOC page 1
author: Unknown
75088.AP.DOC ANDA 75- 088 April 27, 1999 King Pharmaceuticals, IncCromolyn Sodium Ophthalmic Solution USP, 4%)
author: Unknown
75088.AP.DOC page 1
author: Unknown
Microsoft Word - RPSepicPOM Mebendazole 1989 1989: 243: 548 Ovex , Pripsen Dextromethorphan c/ r 1989 1989: 243: 548 Hyoscine Butylbromide 1991 191: 246: 510 Buscopan Nicotine chewing gum 2mg 1991 1991: 246: 510, 552 All products now GSL 6 Vaginal imidazoles 1992 1998: 249: 38,79 Abtrim, Candiden, Daktarin, Canesten, Ecostatin, Fungederm, Gyno- Pevaryl, Hydrocortisone/ crot amiton 1992 1992: 249: 38 Eurax HC...
Microsoft Word - RPSepicPOM page 7
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 7
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 6
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 4
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 3
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 2
http://www.fda.gov/cder/foi/label/2001/18155s22lbl.pdf page 1
Medicines, Ethics and Practice page 9
OP2 outline v2 INNOVATIONS IN OPHTHALMIC PHARMACEUTICALS, 1996Ð 2005 Chapter 1: Executive Summary Research and Development Environment Demographics Major Markets Chapter 2: Introduction Study Objectives Scope and Organization Part I: Environment Part II: Disease and Products Overview Part III: Strategic ...
author: Dan
